3
|
Gu Y, Xu C, Wang Y, Zhou X, Fang L, Cao F. Multifunctional Nanocomposites Based on Liposomes and Layered Double Hydroxides Conjugated with Glycylsarcosine for Efficient Topical Drug Delivery to the Posterior Segment of the Eye. Mol Pharm 2019; 16:2845-2857. [DOI: 10.1021/acs.molpharmaceut.8b01136] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Yan Gu
- Department of Pharmaceutical, School of Pharmacy, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing 210009, China
- Parexel China Co., Ltd., No.488, Middle Yincheng Road, Pudong, Shanghai 200120, China
| | - Chen Xu
- Department of Pharmaceutical, School of Pharmacy, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing 210009, China
| | - Yanyan Wang
- Department of Pharmaceutical, School of Pharmacy, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing 210009, China
| | - Xiangying Zhou
- Department of Pharmaceutical, School of Pharmacy, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing 210009, China
| | - Lei Fang
- Jiangsu Province Hi-Tech Key Laboratory for Bio-medical Research and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China
| | - Feng Cao
- Department of Pharmaceutical, School of Pharmacy, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing 210009, China
| |
Collapse
|
4
|
Wang Y, Xu X, Gu Y, Cheng Y, Cao F. Recent advance of nanoparticle-based topical drug delivery to the posterior segment of the eye. Expert Opin Drug Deliv 2018; 15:687-701. [PMID: 29985660 DOI: 10.1080/17425247.2018.1496080] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
INTRODUCTION Considering that the number of patients afflicted by posterior eye diseases is increasing, effective drug delivery is currently in high clinical demand. Topical administration has been identified as the preferred option, while sufferingfrom multiple barriers. The development of nanoparticle-based drug delivery system provides an option, which would enhance the drug permeability across the barriers and achieve the desired drug level in the targeted tissue. AREAS COVERED This review highlights the barrier to the posterior segment of the eye via topical administration. The up-to-date development of lipid nanoparticles, liposomes, emulsions, spanlastics, micelles, polymeric nanoparticles, layered double hydroxides (LDH), dendrimers, cyclodextrins(CDs), and prodrugs are summarized. Moreover, nanocarriers currently in clinical trials for posterior segment diseases have been discussed. EXPERT OPINION Topical nanoparticle-based drug delivery systems have demonstrated significant progress. An ideal formulation should prolong retention time on the surface, enhance drug permeability through the ocular tissues, and efficiently deliver drugs to the targeted site. To design the rational targeting nanoparticle-based drug delivery system, a better understanding of the distribution of transporters and receptors on the eye is required. Ultimately, there is an urgent need to develop targeting hybrid drug delivery systems with the combination of the advantages of several nanocarriers.
Collapse
Affiliation(s)
- Yanyan Wang
- a Department of Pharmaceutical, School of Pharmacy , China Pharmaceutical University , Nanjing , China
| | - Xiaoyue Xu
- a Department of Pharmaceutical, School of Pharmacy , China Pharmaceutical University , Nanjing , China
| | - Yan Gu
- a Department of Pharmaceutical, School of Pharmacy , China Pharmaceutical University , Nanjing , China
| | - Yanju Cheng
- b Department of Biologics R&D Center , Chia Tai Tianqing Pharmaceutical Group Co. Ltd , Nanjing , China
| | - Feng Cao
- a Department of Pharmaceutical, School of Pharmacy , China Pharmaceutical University , Nanjing , China
| |
Collapse
|
5
|
Adams CM, Anderson K, Artman G, Bizec JC, Cepeda R, Elliott J, Fassbender E, Ghosh M, Hanks S, Hardegger LA, Hosagrahara VP, Jaffee B, Jendza K, Ji N, Johnson L, Lee W, Liu D, Liu F, Long D, Ma F, Mainolfi N, Meredith EL, Miranda K, Peng Y, Poor S, Powers J, Qiu Y, Rao C, Shen S, Sivak JM, Solovay C, Tarsa P, Woolfenden A, Zhang C, Zhang Y. The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. J Med Chem 2018; 61:1622-1635. [PMID: 29400470 DOI: 10.1021/acs.jmedchem.7b01731] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
A noninvasive topical ocular therapy for the treatment of neovascular or "wet" age-related macular degeneration would provide a patient administered alternative to the current standard of care, which requires physician administered intravitreal injections. This manuscript describes a novel strategy for the use of in vivo models of choroidal neovascularization (CNV) as the primary means of developing SAR related to efficacy from topical administration. Ultimately, this effort led to the discovery of acrizanib (LHA510), a small-molecule VEGFR-2 inhibitor with potency and efficacy in rodent CNV models, limited systemic exposure after topical ocular administration, multiple formulation options, and an acceptable rabbit ocular PK profile.
Collapse
Affiliation(s)
- Christopher M Adams
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Karen Anderson
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Gerald Artman
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Jean-Claude Bizec
- Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge Massachusetts 02139, United States
| | - Rosemarie Cepeda
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Jason Elliott
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Elizabeth Fassbender
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Malay Ghosh
- Global Drug Development/Technical Research & Development, Novartis Pharmaceutical Corporation , 6201 South Freeway Fort Worth, Texas 76134-2099, United States
| | - Shawn Hanks
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Leo A Hardegger
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Vinayak P Hosagrahara
- Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge Massachusetts 02139, United States
| | - Bruce Jaffee
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Keith Jendza
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Nan Ji
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Leland Johnson
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Wendy Lee
- Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge Massachusetts 02139, United States
| | - Donglei Liu
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Fang Liu
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Debby Long
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Fupeng Ma
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Nello Mainolfi
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Erik L Meredith
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Karl Miranda
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Yao Peng
- Ocular Pharmacokinetics and Disposition, Alcon, a Novartis Company , 201 South Freeway, Fort Worth, Texas 76134, United States
| | - Stephen Poor
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - James Powers
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Yubin Qiu
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Chang Rao
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Siyuan Shen
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Jeremy M Sivak
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Catherine Solovay
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Peter Tarsa
- Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Amber Woolfenden
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Chun Zhang
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Yiqin Zhang
- Ophthalmology, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
7
|
Grove KJ, Kansara V, Prentiss M, Long D, Mogi M, Kim S, Rudewicz PJ. Application of Imaging Mass Spectrometry to Assess Ocular Drug Transit. SLAS DISCOVERY 2017; 22:1239-1245. [PMID: 28787579 DOI: 10.1177/2472555217724780] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) is becoming an important technology to determine the distribution of drugs and their metabolites in the tissue of preclinical species after dosing. Interest in IMS is growing in the ophthalmology field, but little work to this point has been done to investigate ocular drug transit using this technology. Information on where and how a drug is distributing through the eye is important in understanding efficacy and whether it is reaching the desired target tissue. For this study, ocular distribution of brimonidine was investigated in rabbits following topical administration. Brimonidine has been shown to lower intraocular pressure and is approved to treat glaucoma, the second leading cause of blindness in the world. We have developed IMS methods to assess transit of topically administered brimonidine from the anterior to the posterior segment of rabbit eyes. Using IMS, brimonidine was detected in the cornea, aqueous humor, iris, and posterior segments of the eye. The distribution of brimonidine suggests that the route of transit following topical administration is mainly through the uvea-scleral route. This study demonstrates that IMS can be applied to assess ocular transit and distribution of topically administered drugs.
Collapse
Affiliation(s)
- Kerri J Grove
- 1 Novartis Institutes for BioMedical Research, Emeryville, CA, USA
| | - Viral Kansara
- 2 Novartis Institutes for BioMedical Research, Cambridge, MA, USA
| | - Melissa Prentiss
- 2 Novartis Institutes for BioMedical Research, Cambridge, MA, USA
| | - Debby Long
- 2 Novartis Institutes for BioMedical Research, Cambridge, MA, USA
| | - Muneto Mogi
- 2 Novartis Institutes for BioMedical Research, Cambridge, MA, USA
| | - Sean Kim
- 2 Novartis Institutes for BioMedical Research, Cambridge, MA, USA
| | | |
Collapse
|